Skip to main content

Table 5 Comparing patients with or without interstitial lung disease

From: Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study

 

Patients with ILD

Patients without ILD

P value

(n = 61)

(n = 95)

Male/female

28/33

33/62

0.16

Mean (median) age (years)

69.3 ± 1.6 (71)

67.3 ± 1.3 (71)

0.26

MPO-ANCA

60 (98.3)

70 (73.7)

<0.001

PR3-ANCA

3 (4.9)

15 (15.8)

0.038

Serum creatinine (mg/dl)

1.61 ± 0.23

1.83 ± 0.19

0.45

Disease severity

0.059

 Localised

1 (1.7)

3 (3.1)

 

 Early systemic

21 (34.4)

15 (15.8)

 

 Generalised

31 (50.8)

60 (63.2)

 

 Severe

8 (13.1)

17 (17.9)

 

General performancea

 0/1/2/3/4

11/25/11/12/2

11/33/17/28/6

0.47

BVASb

 BVAS

15.4 ± 1.0

18.4 ± 0.8

0.019

 General

49 (80.3)

69 (72.6)

0.27

 Cutaneous

13 (21.3)

26 (27.4)

0.39

 Mucous membranes/eyes

5 (8.2)

15 (15.8)

0.17

 Ear, nose, and throat

9 (14.8)

33 (34.7)

0.006

 Chest

22 (36.1)

41 (43.2)

0.38

 Cardiovascular

1 (1.7)

11 (11.6)

0.012

 Abdominal

0 (0)

2 (2.1)

0.25

 Renal

44 (72.1)

65 (68.4)

0.62

 Nervous system

28 (45.9)

47 (49.5)

0.66

  1. Values expressed as mean ± standard error or number (percentage) unless otherwise noted. ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; ILD, interstitial lung disease; MPO, myeloperoxidase; MPA, microscopic polyangiitis; PR3, proteinase-3. aGeneral performance was categorised according to the World Health Organization Performance Status except category 5 (death). bDisease activity and patterns of organ involvement were defined by the BVAS 2003 scoring system.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us